No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Press Release: Algernon Pharmaceuticals Announces Closing of Private Placement
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke...
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch,...
Algernon Pharmaceuticals to Move Forward With Psychedelic Drug DMT Stroke Research Program as Its...
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company